Intravesical administration with CaSR agonist ameliorated cystitis-induced bladder hyperactivity, which further suggested the promising potential of the urothelial CaSR as a pharmacotherapeutic target for bladder disorders. The gene discussed is CASR; the disease is chronic cystitis.